Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Add To Watchlist

Recent & Breaking News (NYSE:BMY)

The Reason It Trades, What's Moving WLT, KEY and BMY

Marketwired July 26, 2013

U.S. FDA Acknowledges Receipt of Resubmission of the New Drug Application for Investigational Compound Dapagliflozin for the Treatment of Type 2 Diabetes

Business Wire July 25, 2013

The Real Story Behind NUS, BMY, HON and SBUX

Marketwired July 25, 2013

Bristol-Myers Squibb Reports Second Quarter 2013 Financial Results

Business Wire July 25, 2013

Perfect Trade Setups, How to Play AMGN, MCD, BMY and PM

Marketwired July 25, 2013

FDA Accepts Eliquis® (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery

Business Wire July 11, 2013

Technical Scrutiny: Bristol-Myers Squibb, Eli Lilly & Co., Allergan, and Endo Pharma

PR Newswire July 9, 2013

Positive Results, Exclusive Agreements, and Orphan Drug Designations - Research Report on Bristol-Myers Squibb, Illumina, Alexion, Health Net, and Emeritus

PR Newswire July 8, 2013

Bristol-Myers Squibb to Announce Results for Second Quarter 2013 on July 25

Business Wire July 1, 2013

Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of Acute Venous Thromboembolism

Business Wire June 30, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BMY, DD, DOM and LLY

Accesswire June 27, 2013

Gaining Momentum from Regulatory Wins, Improved Product Labeling, and Leadership Changes - Research Report on Bristol-Myers Squibb, Celgene, Aetna, Theravance, and MannKind

PR Newswire June 26, 2013

Oxford BioTherapeutics Appoints Bryan G. Morton as Chairman

PR Newswire June 26, 2013

The Zacks Analyst Blog Highlights:Cummins, Eli Lilly, Bristol-Myers Squibb, Merck and Novo Nordisk

PR Newswire June 25, 2013

Phase IIa Study Assessing Safety and Tolerability of Dapagliflozin after 14 Days as Add-on to Insulin in Adult Patients with Type 1 Diabetes Presented at the 2013 American Diabetes Association Scientific Sessions®

Business Wire June 22, 2013

FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib) to Include Three-Year First-Line and Five-Year Second-Line Efficacy and Safety Data in Chronic Myeloid Leukemia in Chronic Phase

Business Wire June 20, 2013

Capital Construction Mid-Year Snapshot: Pharma-Bio Industry to Invest More Than $16 Billion in 2013 Project Starts, an Industrial Info News Alert

Marketwired June 20, 2013

Bristol-Myers Squibb Names Dinesh C. Paliwal to Board of Directors

Business Wire June 19, 2013

Bristol-Myers Squibb Announces Dividend

Business Wire June 19, 2013

AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin)

Business Wire June 19, 2013